When does Synagis (palivizumab) patent protection expire?
Synagis’ effective protection dates depend on which patent(s) you mean (drug substance, formulations, manufacturing, or method-of-use), and on the country. The specific expiry schedule isn’t provided in the available information here, so I can’t state exact Synagis patent expiry dates without risking errors.
What matters more than the “patent expiry date” for Synagis—exclusivity and market availability?
Even if a particular patent expires, market entry can still be delayed by other forms of protection (for example, additional patents covering related claims, or regulatory exclusivity rules). Those timelines vary by jurisdiction and by the exact claim being challenged or cleared.
How to get the exact expiry dates you need (country + patent family)
To provide precise “patent expiry dates,” I need at least:
- Which country or region (US, EU/EP, UK, etc.)
- Whether you want the latest protection date (most relevant for generic/biosimilar timing) or a specific patent number/patent family
If you share the jurisdiction (or the patent numbers you’ve seen in a dossier), I can map the expected expiry dates by claim type using the relevant legal record.
Are there “biosimilar” or “generic” timelines tied to Synagis patents?
Synagis is a biologic (palivizumab), so the competitive timeline is usually driven by when biosimilar developers can enter. That timing typically reflects patent and regulatory exclusivity status, not just one single patent expiry date.
Quick next step
Tell me the jurisdiction (for example, “United States”) and whether you mean palivizumab patents in general or the specific Synagis patent(s) you found. Then I can give the exact expiry dates you’re looking for.
Sources
No source links were provided in the prompt, so I did not cite any.